MaxCyte, Inc. (NASDAQ:MXCT - Get Free Report) Director John Joseph Johnston sold 3,000 shares of the firm's stock in a transaction that occurred on Monday, October 28th. The shares were sold at an average price of $3.72, for a total transaction of $11,160.00. Following the completion of the sale, the director now owns 141,950 shares in the company, valued at approximately $528,054. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.
John Joseph Johnston also recently made the following trade(s):
- On Thursday, September 26th, John Joseph Johnston sold 3,000 shares of MaxCyte stock. The shares were sold at an average price of $3.82, for a total transaction of $11,460.00.
- On Monday, August 26th, John Joseph Johnston sold 3,000 shares of MaxCyte stock. The stock was sold at an average price of $4.28, for a total transaction of $12,840.00.
MaxCyte Stock Down 0.8 %
NASDAQ MXCT opened at $3.54 on Thursday. The company has a market cap of $372.30 million, a price-to-earnings ratio of -10.41 and a beta of 1.39. MaxCyte, Inc. has a twelve month low of $2.92 and a twelve month high of $5.55. The business's fifty day moving average is $3.92 and its 200 day moving average is $4.19.
I was wrong. Dead wrong.
From Porter & Company | Ad
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was.
Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
Here’s the full story for you.
MaxCyte (NASDAQ:MXCT - Get Free Report) last announced its quarterly earnings results on Tuesday, August 6th. The company reported ($0.09) EPS for the quarter, beating analysts' consensus estimates of ($0.14) by $0.05. The firm had revenue of $10.43 million for the quarter, compared to analyst estimates of $8.20 million. MaxCyte had a negative return on equity of 15.52% and a negative net margin of 77.97%. During the same period last year, the firm posted ($0.10) earnings per share. On average, research analysts anticipate that MaxCyte, Inc. will post -0.44 earnings per share for the current fiscal year.
Hedge Funds Weigh In On MaxCyte
Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Swedbank AB bought a new stake in shares of MaxCyte in the first quarter worth $6,704,000. Chevy Chase Trust Holdings LLC lifted its holdings in MaxCyte by 2,182.6% during the 1st quarter. Chevy Chase Trust Holdings LLC now owns 1,296,397 shares of the company's stock worth $5,432,000 after buying an additional 1,239,602 shares during the period. Marshall Wace LLP bought a new stake in shares of MaxCyte in the 2nd quarter valued at about $1,959,000. River Global Investors LLP increased its stake in shares of MaxCyte by 24.4% in the first quarter. River Global Investors LLP now owns 1,888,642 shares of the company's stock valued at $7,973,000 after buying an additional 369,996 shares during the period. Finally, Dimensional Fund Advisors LP raised its position in shares of MaxCyte by 13.6% during the second quarter. Dimensional Fund Advisors LP now owns 1,010,292 shares of the company's stock worth $3,961,000 after acquiring an additional 121,090 shares during the last quarter. 68.81% of the stock is currently owned by institutional investors and hedge funds.
MaxCyte Company Profile
(
Get Free Report)
MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
